Trial Outcomes & Findings for Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding (NCT NCT00582946)

NCT ID: NCT00582946

Last Updated: 2016-11-04

Results Overview

A primary outcome measure of interest is an estimate of the insitu maximum equivalent pressure output (MEPO) of the EarLens system, which represents the sound pressure level that would have to be applied at the eardrum (or tympanic membrane) to produce the same degree of tympanic membrane (TM) vibration that the EarLens system produces with the coil current set to its maximum value, and given the anatomical constraints on the coupling between the coil and magnet for a given subject. The target fitting range included hearing loss up to 60 decibels (dB) Hearing Level (HL). In order for the device to be an effective hearing aid for this target population, the maximum output of the device needs to be able to provide output and gain to treat this maximum hearing loss.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

16 participants

Primary outcome timeframe

1 month

Results posted on

2016-11-04

Participant Flow

Participant milestones

Participant milestones
Measure
Magnetic Contact Hearing Aid
Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
Overall Study
STARTED
16
Overall Study
COMPLETED
16
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Magnetic Contact Hearing Aid
n=16 Participants
Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
8 Participants
n=5 Participants
Age, Categorical
>=65 years
8 Participants
n=5 Participants
Age, Continuous
65 years
STANDARD_DEVIATION 8 • n=5 Participants
Sex: Female, Male
Female
8 Participants
n=5 Participants
Sex: Female, Male
Male
8 Participants
n=5 Participants
Region of Enrollment
United States
16 participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 month

A primary outcome measure of interest is an estimate of the insitu maximum equivalent pressure output (MEPO) of the EarLens system, which represents the sound pressure level that would have to be applied at the eardrum (or tympanic membrane) to produce the same degree of tympanic membrane (TM) vibration that the EarLens system produces with the coil current set to its maximum value, and given the anatomical constraints on the coupling between the coil and magnet for a given subject. The target fitting range included hearing loss up to 60 decibels (dB) Hearing Level (HL). In order for the device to be an effective hearing aid for this target population, the maximum output of the device needs to be able to provide output and gain to treat this maximum hearing loss.

Outcome measures

Outcome measures
Measure
Maximum Equivalent Pressure Output
n=16 Participants
Provision of amplification to treat sensorineural hearing loss with direct-drive hearing aid for acute evaluation of efficacy.
Maximum Effective Sound Pressure Level (MEPO)
95 decibels (dB) Sound Pressure Level (SPL)
Standard Deviation 7

Adverse Events

Magnetic Contact Hearing Aid

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sunil Puria

EarLens Corporation

Phone: 650-366-9000

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place